Several existing drugs provide patient benefit as the cancer cells are believed to continue to adapt and develop resistance. Research indicates that combination therapies which include drugs with different mechanisms of action impact cancer cells in multiple ways may provide an alternative treatment option.

Tyrogenex is dedicated to developing drugs with the potential for reduced toxicity to provide a broader therapeutic window. We believe this design objective creates drug candidates which are ideally suited to be used in combination.

Phase 2 combination clinical trials are currently enrolling.